Metabolic disposition and pharmacokinetics of [14C]-amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered as a single oral dose to healthy male subjects

Journal of Clinical Pharmacology

Volumn 41, Issue 4, 2001, Pages 386-396

  Sadler, B M ^a   Chittick, G E ^a   Polk, R E ^a   Slain, D ^a   Kerkering, T M ^a   Studenberg, S D ^a   Lou, Y ^a   Moore, K H P ^a   Woolley, J L ^a   Stein, D S ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DRUG DETERMINATION; DRUG EFFECT; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; METABOLIC ACTIVATION; QUALITY OF LIFE; SURVIVAL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ANTI-HIV AGENTS; BREATH TESTS; CARBAMATES; CARBON RADIOISOTOPES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FOLLOW-UP STUDIES; HALF-LIFE; HIV SERONEGATIVITY; HIV-1; HUMANS; MALE; MIDDLE AGED; PROTEASE INHIBITORS; SULFONAMIDES;

EID: 17744390345     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700122010249     Document Type: Article

References (38)

1. Antiretroviral therapy in adults: Updated recommendations of the international AIDS society-USA panel
2. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents
3. 1998 Revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals
4. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
5. Triple therapy with AZT and 3TC in combination with nelfinavir mesylate in 12 antiretroviral-naive subjects chronically infected with HIV-1
6. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
7. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centers
8. HIV-protease inhibitors
9. Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management
10. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group
11. In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents
12. Pharmacokinetic (PK) drug-interaction between amprenavir (APV) and ritonavir in HIV-seronegative subjects after multiple, oral dosing
13. Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults
14. A pharmacokinetic and pharmacodynamic study of the HIV protease inhibitor amprenavir after multiple oral dosing
15. Cytochrome P-450 isoenzyme induction, inhibition, and metabolism studies with the HIV protease inhibitor, 141W94
16. Metabolism of amprenavir in liver microsomes: Role of CYP3A4 inhibition for drug interactions
17. 14C]-amprenavir in human volunteers
18. 14C-141W94 (VX-478), an HIV-1 protease inhibitor
19. 14C]-amprenavir in rats
20. Effect of demographic, laboratory, and clinical covariates on the pharmacokinetics (PK] of amprenavir (APV)
21. Predicting drug interactions in vivo from experiments in vitro: Human studies with paclitaxel and ketoconazole
22. Pharmacokinetic quantification of the exchange of drugs between blood and cerebrospinal fluid in man
23. In vitro metabolism of a potent HIV-protease inhibitor (141W94) using rat, monkey and human liver S9
24. Plasma protein binding and erythrocyte partitioning studies in rats, dogs, and humans with the HIV-1 protease inhibitor, 141W94 (VX-478)
25. Ethnic differences in drug disposition and responsiveness
26. 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease
27. Influence of race or ethnicity on pharmacokinetics of drugs
28. Non-invasive tests of CYP3A enzymes
29. Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans
30. Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs and humans
31. Indinavir product information
32. Nelfinavir product information
33. Saquinavir product information
34. The neuropathogenesis of the AIDS dementia complex
35. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
36. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor